Sidroga Löwenzahntee

Informazioni principali

  • Nome commerciale:
  • Sidroga Löwenzahntee geschnittene Droge
  • Forma farmaceutica:
  • geschnittene Droge
  • Composizione:
  • radix taraxaci cum herba 1,5 g pro charta.
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Erbe per uso umano

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Sidroga Löwenzahntee geschnittene Droge
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Phytoarzneimittel
  • Area terapeutica:
  • Bei Verdauungsbeschwerden

Altre informazioni

Status

  • Fonte:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Numero dell'autorizzazione:
  • 44554
  • Data dell'autorizzazione:
  • 20-07-1982
  • Ultimo aggiornamento:
  • 18-10-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Patienteninformation

Sidroga® Tisana tarassaco

Sidroga AG

Medicamento fitoterapeutico

Che cos’è la tisana al tarassaco Sidroga e quando si usa?

La tisana di tarassaco Sidroga contiene erba e radice di tarassaco (dente di leone) in forma essiccata e

in qualità tritata finemente. Secondo la tradizione all'erba e radice di tarassaco sono attribuite

proprietà che facilitano la digestione e stimolano l'appetito. La tisana al tarassaco Sidroga si usa in

caso d'inappetenza e disturbi digestivi.

Di che cosa occorre inoltre tener conto durante il trattamento?

Si rivolga al medico in caso d'inappetenza e disturbi digestivi persistenti o ricorrenti, in modo che il

medico trovi la loro causa. Dolori allo stomaco che si manifestano con un male ad un punto

determinato, oppure dolori al tattoo o che sono legati ad un malessere generale, richiedono una

consultazione medica. Si ricordi che certi generi voluttuari, quali caffè, alcol, nicotina, come pure

certi medicamenti, quali analgesici ed antireumatici, possono provocare disturbi allo stomaco.

Occorre rivolgersi al medico, perché appuri la causa di disturbi digestivi in bambini sotto i 12 anni.

Per questa fascia d'età, quindi, non si deve usare il preparato senza previa consultazione del medico.

Quando non si può usare la tisana al tarassaco Sidroga e quando la sua somministrazione richiede

prudenza?

La tisana al tarassaco Sidroga non deve essere usata in caso di ipersensibilità nota al tarassaco. La

tisana al tarassaco Sidroga deve essere consumata in caso di gravi disturbi agli organi digerenti,

come infiammazione od ostruzione delle vie biliari, solo dopo la consultazione del medico.

Poiché i disturbi digestivi nei bambini sotto i 12 anni devono essere chiariti da un medico, l'uso di

questo medicamento in questi casi non è raccomandato senza consiglio medico.

Informi il suo medico, il suo farmacista o il suo droghiere nel caso in cui

·soffre di altre malattie

·soffre di allergie o

·assume altri medicamenti (anche acquistati di sua iniziativa!).

Si può assumere la tisana al tarassaco Sidroga durante la gravidanza o l’allattamento?

In base alle esperienze fatte finora, non sono noti rischi per il bambino se il medicamento è usato

correttamente. Tuttavia, non sono state eseguite indagini scientifiche sistematiche. Per prudenza

dovrebbe rinunciare nella misura del possibile ad assumere medicamenti durante la gravidanza e il

periodo d'allattamento o chiedere consiglio al proprio medico, farmacista o droghiere.

Come usare la tisana al tarassaco Sidroga?

Adulti e adolescenti a partire da 12 anni prendono in caso d'inappetenza una tazza mezz'ora prima dei

pasti; in caso di flatulenze o sensazione di replezione 1 tazza dopo i pasti.

Preparazione: 1 bustina per 1 tazza. Versare dell'acqua bollente, lasciare in infusione durante 5 a 10

minuti e levare la bustina.

La presa di molto liquido è importante.

Si attenga alla posologia indicata nel foglietto illustrativo o prescritta dal suo medico. Se ritiene che

l'azione del medicamento sia troppo debole o troppo forte ne parli al suo medico, al suo farmacista o

al suo droghiere.

Quali effetti collaterali può avere la tisana al tarassaco Sidroga?

In seguito alla presa della tisana al tarassaco Sidroga possono essere osservati i seguenti effetti

collaterali: occasionalmente disturbi allo stomaco o leggera diarrea.

Se osserva effetti collaterali qui non descritti dovrebbe informare il suo medico, il suo farmacista o il

suo droghiere.

Di che altro occorre tener conto?

La tisana al tarassaco Sidroga deve essere conservata a temperatura ambiente (15-25 °C) e fuori dalla

portata dei bambini.

Le bustine a doppio filtro con protezione aroma non devono essere utilizzate oltre la data indicata

con «Exp.» sul contenitore.

Il medico, il farmacista o il droghiere possono darle ulteriori informazioni.

Cosa contiene la tisana al tarassaco Sidroga?

1 bustina a doppio filtro contiene 1,5 g di erba e radice di tarassaco essiccate e tritate finemente.

Numero dell’omologazione

44554 (Swissmedic).

Dove è ottenibile la tisana al tarassaco Sidroga? Quali confezioni sono disponibili?

In farmacia e in drogheria, senza prescrizione medica.

Confezioni da 20 bustine a doppio filtro con protezione aroma.

Titolare dell’omologazione

Sidroga AG, 4310 Rheinfelden.

Questo foglietto illustrativo è stato controllato l'ultima volta nel settembre 2010 dall'autorità

competente in materia di medicamenti (Swissmedic).

17-1-2019

Outcome of the public consultation on the draft statement on genotoxicity assessment of chemical mixtures

Outcome of the public consultation on the draft statement on genotoxicity assessment of chemical mixtures

Published on: Wed, 16 Jan 2019 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the genotoxicity assessment of chemical mixtures. The draft statement was prepared by a dedicated working group of the Scientific Committee and endorsed by the Scientific Committee for public consultation at its 89th plenary meeting of 28‐29 May 2018. The public consultation for this document was open from 26 June until 9 ...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Outcome of the Public Consultation on the draft Guidance on Communication of Uncertainty in Scientific Assessments

Outcome of the Public Consultation on the draft Guidance on Communication of Uncertainty in Scientific Assessments

Published on: Wed, 16 Jan 2019 The first strategic objective of EFSA's strategy 2020 ‘Trusted science for safe food’ is the prioritisation of public and stakeholder engagement in the development of scientific assessment. To achieve this, objective public consultations are a key step for such a strategic framework. The draft Guidance document on communication of uncertainty underwent a web‐based public consultation from 4 May to 24 June 2018. The document provides guidance for communicators on how to com...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Genotoxicity assessment of chemical mixtures

Genotoxicity assessment of chemical mixtures

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Guidance on Communication of Uncertainty in Scientific Assessments

Guidance on Communication of Uncertainty in Scientific Assessments

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-11-2018

Foreign Product Alert: Black Lion Pill, Help 100% & Pure Natural & Body Slim capsules, Herba Saraf, Horny Little Devil, Ja Dera Max capsules, Lida (Plus) capsules, Nutra Organics Green Tea Extract capsules, Papapa, Red Zone Xtreme 3000, Rhino 69 Extreme 5

Foreign Product Alert: Black Lion Pill, Help 100% & Pure Natural & Body Slim capsules, Herba Saraf, Horny Little Devil, Ja Dera Max capsules, Lida (Plus) capsules, Nutra Organics Green Tea Extract capsules, Papapa, Red Zone Xtreme 3000, Rhino 69 Extreme 5

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients and/or unacceptable contaminant(s).

Health Canada

15-11-2018

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Published on: Wed, 14 Nov 2018 The technical report reflects the outcome of the discussions and agreements that were reached in the pesticides peer review meeting on residues and maximum residue levels regarding the principles and guidance for application of the proportionality concept in the risk assessment methodologies used at European level for the estimation of the maximum residue levels for pesticides. In addition, practical experiences on the use of the proportionality approach gained by EFSA hav...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Training courses in systematic reviews or in specific steps of systematic review for EFSA Risk Assessment

Training courses in systematic reviews or in specific steps of systematic review for EFSA Risk Assessment

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. Th...

Europe - EFSA - European Food Safety Authority Publications

26-9-2018

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Published on: Tue, 25 Sep 2018 00:00:00 +0200 Abstract Following a notification from Sorghum Zrt., submitted to the European Commission under Article 14 of Regulation (EU) 2015/2283 to place on the market syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country (TF), and in line with Article 15(2) of that Regulation, EFSA was asked by the European Commission whether there are duly reasoned safety objections to the placing on the market of the TF within the European Union. The ap...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Public Notification: BodySlim Herbal contains hidden drug ingredient

Public Notification: BodySlim Herbal contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use BodySlim Herbal, a product promoted for weight loss. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

30-8-2018

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Cyprus and EFSA – Final report

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in Cyprus and EFSA – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 Cyprus alongside with another 4 countries has participated successfully in the Grant Agreement GP/EFSA/DATA/2016/01‐GA 02, entitled: “Strategic Partnership with Cyprus on Data Quality”. The project was co‐financed by EFSA, aiming to help both EFSA and data providers from Member States to possess data of high quality in a quantitatively manageable way. The main objective of the grant agreement was the establishment of the data governance, coordination and imp...

Europe - EFSA - European Food Safety Authority Publications

14-8-2018

Scientific guideline:  Procedure for the review and revision of European Union herbal monographs and European Union list entries - Revision 2, adopted

Scientific guideline: Procedure for the review and revision of European Union herbal monographs and European Union list entries - Revision 2, adopted

The purpose of this procedure is to enable a consistent and proportionate process in reviewing and revising all European Union herbal monographs and European Union list entries adopted by the HMPC. The aim of this document is to describe how to identify the criteria/reasons that trigger the revision of European Union herbal monographs and list entries and the associated procedure and timelines for both the review and the revision.

Europe - EFSA - European Food Safety Authority EFSA Journal

29-5-2018

Newly Added Guidance Documents

Newly Added Guidance Documents

Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

FDA - U.S. Food and Drug Administration

24-4-2018

One lot of Traditional Medicinals "Throat Coat Lemon Echinacea" herbal tea recalled because of potential contamination with Salmonella

One lot of Traditional Medicinals "Throat Coat Lemon Echinacea" herbal tea recalled because of potential contamination with Salmonella

Health Canada is advising Canadians that one lot of “Throat Coat Lemon Echinacea” herbal tea is being voluntarily recalled by Traditional Medicinals after a company supplier found Salmonella contamination in a tea ingredient (lemon myrtle leaf). An infection caused by Salmonella bacteria may pose serious health risks, particularly for young children, pregnant women, the elderly and people with weak immune systems.

Health Canada

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

18-9-2018

Herbal medicinal products:  Avena , Avenae herba, Avena sativa L.

Herbal medicinal products: Avena , Avenae herba, Avena sativa L.

Europe - EMA - European Medicines Agency

5-9-2018

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments:  h

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments: h

#FDA announces draft guidance: Consideration of Uncertainty in Making Benefit-Risk Determinations in #MedicalDevice Premarket Approvals. The document is now open for comment for 90 days. Click the link to review the draft guidance and provide comments: https://go.usa.gov/xPcpT  pic.twitter.com/hAuLWaIYiK

FDA - U.S. Food and Drug Administration

27-8-2018

Submissions received: Discontinuing pre-market evaluation of Herbal Component Names (HCNs)

Submissions received: Discontinuing pre-market evaluation of Herbal Component Names (HCNs)

Submissions received on the Discontinuing pre-market evaluation of Herbal Component Names (HCNs) consultation have been published

Therapeutic Goods Administration - Australia

17-8-2018

Scientific guideline:  Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3, draft: consultation open

Scientific guideline: Draft guideline on clinical investigation of medicinal products in the treatment of epileptic disorders - Revision 3, draft: consultation open

The present document is a third revision of the existing guideline. It should be considered as general guidance on the development of medicinal products for the treatment of epileptic disorders and should be read in conjunction with other EMA and ICH guidelines, which may apply to these conditions and patient populations. The main changes to the existing guideline include incorporation of the new classification / definitions of seizure types and epilepsies, the acceptance of add-on studies in support o...

Europe - EMA - European Medicines Agency

15-8-2018

Scientific guideline:  Draft guideline on quality of herbal medicinal products/traditional herbal medicinal products - Revision 3 , draft: consultation open

Scientific guideline: Draft guideline on quality of herbal medicinal products/traditional herbal medicinal products - Revision 3 , draft: consultation open

This document intends to cover the general quality aspects of herbal medicinal products for human and veterinary use, including traditional herbal medicinal products for human use. It describes the special problems of herbal medicinal products and the differences between medicinal products containing chemically defined active substances.

Europe - EMA - European Medicines Agency

15-8-2018

Scientific guideline:  Draft guideline on specifications: test procedures and acceptance criteria for herbal  substances, herbal  preparations and herbal medicinal products/traditional herbal medicinal products - Revision 3 , draft: consultation open

Scientific guideline: Draft guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products - Revision 3 , draft: consultation open

This document addresses specifications, i.e. those tests, procedures, and acceptance criteria used to assure the quality of the herbal substances/preparations and herbal medicinal products at release and during the shelf-life.

Europe - EMA - European Medicines Agency

12-8-2018

IMDRF consultation: Unique Device Identification system

IMDRF consultation: Unique Device Identification system

The IMDRF is seeking comments on a proposed guidance document and two information documents

Therapeutic Goods Administration - Australia

27-6-2018

Regulatory and procedural guideline:  Quality Review of Documents general principles regarding the summary-of-product-characteristics information for a generic / hybrid / biosimilar product

Regulatory and procedural guideline: Quality Review of Documents general principles regarding the summary-of-product-characteristics information for a generic / hybrid / biosimilar product

This document outlines the general principles to follow for the preparation of the summary of product characteristics (SmPC) for a generic, hybrid or biosimilar medicinal product to be authorised via the centralised procedure using a reference medicinal product authorised either at national level or centrally.

Europe - EMA - European Medicines Agency